AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
The deal could create one of the world's biggest pharmaceutical groups with a combined value of nearly $400 billion.
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times. The megadeal would be one of the largest in history, creating a combined company valued at $400 billion.
AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports
UK drugmaker AstraZeneca has been exploring a deal to combine with U.S. rival Bristol Myers Squibb , the Financial Times reported on Sunday, citing people familiar with the matter.
AstraZeneca's drug pipeine is splitting opinion among City analysts
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drug pipeline is splitting opinion among City brokers, with Citibank upgrading its price target to 17,800p whilst analysts at Deutsche Bank repeated a 'sell' rating and a 11,500p valuation. Shares in the FTSE 100 drugmaker were down 1.1% at 12,744p on Tuesday afternoon.
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Transcript
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Transcript
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
AstraZeneca tops Q2 earnings and revenue estimates as strong demand for oncology and rare disease drugs helps offset growing generic competition across key products.
AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks
AstraZeneca PLC delivered solid Q2 2026 core EPS growth of 18% YoY, while revenue growth came in line with expectations for the full year 2026. There could be challenges in store, though, with Farxiga, the company's biggest treatment, seeing patent expiry in the U.S. and coming under China's procurement program. Balancing out the challenges to some extent are the results of the company's weight loss drug candidate, elecoglipron, and the stock's improved market valuations.
Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Astrazeneca (AZN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Astrazeneca Q2 Earnings Call Highlights
Astrazeneca NYSE: AZN reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per share increased 11%. The company reiterated its full-year outlook and said it remains confident in its goal of reaching $80 billion in revenue by 2030.
AstraZeneca drug prices evolving in response to Trump policy, executive says
AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President Donald Trump's "most-favoured-nation" policy seeking lower drug prices for Americans, a senior company executive said on Monday.
AstraZeneca's rare disease drug misses main goal in late-stage trial
AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant, the latest in a series of setbacks this year that have fuelled concerns about the drugmaker's pipeline.
AstraZeneca earnings beat forecasts despite slight revenue miss
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reported better second-quarter earnings than expected as growth in oncology and rare diseases helped offset weaker sales elsewhere. Total revenue increased 9% to $30.7 billion in the first half of 2026, or 6% at constant exchange rates.
